⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2485221 | 0.82 | KCNH2 (0.50) | — | |
| SCHEMBL45869 | 0.82 | KCNH2 (0.52) | — | |
| SCHEMBL8739934 | 0.80 | PARP1 (0.46) | — | |
| SCHEMBL11564452 | 0.79 | KCNH2 (0.50) | — | |
| SCHEMBL11904336 | 0.79 | KCNH2 (0.62) | — | |
| SCHEMBL29561513 | 0.78 | — | — | |
| SCHEMBL506617 | 0.78 | — | — | |
| SCHEMBL23895431 | 0.77 | KDM1A (0.45) | — | |
| SCHEMBL7498162 | 0.77 | HTR7 (0.41) | — | |
| SCHEMBL5907729 | 0.77 | KCNH2 (0.71) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2025076285-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-3870577-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2025-03-19 | — | — | EP | disclosed |
| EP-4288429-A1 | LACTAMS AS CBL-B INHIBITORS | Genentech, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-117177970-A | Polycyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| CN-116888112-A | Lactams as CBL-B inhibitors | 基因泰克公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023171783-A1 | PYRAZOLE COMPOUND, AND NOXIOUS ORGANISM CONTROL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | 三井化学アグロ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| US-11737463-B2 | Pyridine and pyrazine compounds | BASF SE (DE) | 2023-08-29 | — | — | US | disclosed |
| CN-1585762-A | Pyridine derivatives as NMDA receptor ligands | HOFFMANN LA ROCHE (CH) | 2005-02-23 | — | — | CN | disclosed |
| CN-1578662-A | Pyridine derivatives as nmda-receptor subtype blockers | HOFFMANN LA ROCHE (CH) | 2005-02-09 | — | — | CN | disclosed |
| US-6831087-B2 | 2-(Pyrid-2- or 4-yl)-1,2,3,4-tetrahydroisoquinoline and derivatives; a good affinity to the NMDA receptor (N-methyl-D-asparate); acute/cronic neurodegenerative diseases; bacterial/viral infections; antidepressants; analgesics | HOFFMANN-LA ROCHE INC. | 2004-12-14 | — | — | US | disclosed |
| EP-1448547-A1 | PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-25 | — | — | EP | disclosed |
| EP-1443926-A1 | PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-11 | — | — | EP | disclosed |
| US-20040068118-A1 | Conjugated aromatic compounds with a pyridine substituent | ALANINE ALEXANDER (FR) | 2004-04-08 | — | — | US | disclosed |
| US-20030144525-A1 | Conjugated aromatic compounds with a pyridine substituent | HOFFMANN-LA ROCHE INC. | 2003-07-31 | — | — | US | disclosed |
| US-20030119870-A1 | Pyridine substituted isoquinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-26 | — | — | US | disclosed |
| WO-2003040128-A1 | PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003037333-A1 | PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |